ArticleNPJ precision oncology2026
Multimodal AI model for early detection of hepatocellular carcinoma.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Detection of early hepatocellular carcinoma (eHCC) is important for timely treatment and improved prognosis. However, it is challenging to distinguish eHCC from pre-malignant high-grade dysplastic nodules (HGDN). Here we developed an artificial intelligence (AI) derived computational framework to identify potential biomarkers and built classification models for eHCC and HGDN. A two-stage multiscale deep learning model (TMC-net) captured the subtle features based on H&E images, and outperformed the pathology foundation model and traditional histopathological features. The learned features were consistent with clinical diagnostic criteria and could be highlighted on the virtual images, assisting junior pathologists in improving the diagnostic accuracy. Four marker genes were screened through comparative transcriptome analysis. The multimodal model based on marker genes and histopathological features achieved AUROC of 0.8875 and 0.9500 on the internal and external test sets, respectively. We confirmed the morpho-phenotype correlations of these genes and found that the multimodal features were associated with patient prognosis in a broader HCC cohort. This study reveals histopathological and transcriptomic features of eHCC, and provides an optimized AI solution for assistant diagnosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.